A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovir D...

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-005769-36

A Phase IV, Open-label, Prospective Observational Study to Evaluate Virological Response in Antiretroviral-Experienced HIV-1 infected Subjects Switching to Atripla (efavirenz/emtricitabine/tenofovir DF) on an Empty Stomach

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate pure virological response rates (defined as subjects who do not have pure virologic failure at HIV-1 RNA threshold of 50 copies/mL) in antiretroviral-experienced subjects receiving Atripla for 48 weeks on an empty stomach.


Critère d'inclusion

  • Antiretroviral-experienced HIV 1 infected subjects on their first and stable HAART regimen of efavirenz, emtricitabine, and tenofovir DF

Liens